400cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 42, Issue 11, 2008, Pages 715-722

  Sobecks, R M ^a   Dean, R ^a   Rybicki, L A ^b   Chan, J ^a   Theil, K S ^b   Macklis, R ^b   Andresen, S ^a   Kalaycio, M ^a   Pohlman, B ^a   Ferraro, C ^a   Cherni, K ^a   Sweetenham, J ^a   Copelan, E ^a   Bolwell, B J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG TOXICITY; MALE; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; SHORT TANDEM REPEAT; SKIN TOXICITY; T LYMPHOCYTE; THERMOLUMINESCENCE DOSIMETRY; TREATMENT DURATION; VIRUS INFECTION; WHOLE BODY RADIATION; BLOOD DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 58149478114     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.248     Document Type: Article

References (32)

1. Niederwieser D, Maris M, Shizuru J, Petersdorf E, Hegenbart U, Sandmaier B et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
4. Giralt S, Thall PF, Khouri I, Wang X, Braunshweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
5. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier B, Molina A, Maloney D et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
6. Scott BL, Sandmaier BM, Storer B, Marris M, Sorror M, Maloney D et al Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006; 20: 128-135.
7. Maris MB, Sandmaier BM, Storer B, Agura E, Wade J, Maziarz R et al Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. Blood 2005; 106: 329a (abstract no. 1130).
8. Sobecks RM, Ball EJ, Askar M, Theil K, Rybicki L, Thomas D et al. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 709-714.
9. Paul P, Apgar J, Ball EJ. HLA-DRB1* intron-primed sequencing for haploid genotyping. Clin Chem 2003; 49: 692-694.
10. Paul P, Thomas D, Kawczak P, Good D, Cook DJ, Ball EJ. Resolution of cis-trans ambiguities between HLA-DRB1 alleles using single-strand conformation polymorphisms and sequencing. Tissue Antigens 2001; 57: 300-307.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957; 53: 457-481.
14. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risk failure data. Stat Med 1993; 12: 737-751.
15. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
16. Chakraverty R, Peggs K, Chopra R, Milligan D, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
17. Taussig D, Davies A, Cavenagh J, Oakervee H, Syndercombe-Court D, Kelsey S et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003; 21: 3060-3065.
18. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
19. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
20. Champlin R, Khouri I, Saliba R, Cohen A, de Lima M, Giralt S. Dose matters: Improved disease control with increased cytoreduction in nonablative BMT for late chronic and accelerated phase CML. Blood 2001; 98: 478a (abstract no. 1996).
21. Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Devine S et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant. 2006; 12: 749-757.
22. Kahl C, Mielcarek M, Iwata M, Harkey M, Storer B, Torok-Storb B. Radiation dose determines the degree of myeloid engraftment after nonmyeloablative stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 826-833.
23. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34: 1083-1088.
24. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland M, Heinecke A et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005; 106: 3314-3321.
25. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
26. Antin J, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings. Biol Blood Marrow Transplant 2001; 7: 473-485.
27. Baron F, Baker J, Storb R, Gooley TA, Sandmaier BM, Maris MB et al Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254-2262.
28. + dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in solid tumor patients. Blood 2004; 103: 1560-1563.
29. Valcarcel D, Martino R, Caballero D, Mateos MV, Pérez-Simón JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
30. Fung H, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G et al. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 2003; 9: 649-656.
31. Baron F, Storb R, Storer B, Maris M, Niederwieser D, Shizuru J et al Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150-4157.
32. Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L et al. Nonmyeloablative allogeneic hematopoietic transplantation: A promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419-2423.